Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Botensilimab and Balstilimab for MMRp/MSS Rectal Adenocarcinoma
NCT06843434Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of botensilimab, balstilimab in rectal adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2025; status: recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT06843434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843434.